Search

The funding will support patient navigation, essential needs, telemedicine, and psychosocial support services, including language translation and interpretation.

… Wednesday, September 21, 2022 The Immigrant Health and Cancer Disparities Service (IHCD) at Memorial Sloan Kettering Cancer Center (MSK) has received a five-year grant that will help advance health equity in New York and beyond. The grant, from the Merck Foundation as part of its Alliance for Equity

Dennis Chi lists the most important things to remember about ovarian cancer.

… Thursday, August 22, 2024 Ovarian cancer  is considered a rare disease. About 20,000 women in the United States will be diagnosed with it in 2024, according to the American Cancer Society. Dennis Chi, MD , Deputy Chief of the Gynecology Service and Head of Ovarian Cancer Surgery at Memorial Sloan Kettering

Learn about renowned cellular lipid and energy metabolism researchers Robert Farese, Jr., and Tobias Walther who recently joined the Sloan Kettering Institute, running their lab jointly.

… Monday, November 21, 2022 Over nearly two decades, Robert Farese, Jr., and Tobias Walther have charted a scientific partnership based on a simple formula: 1 + 1 = 3. That is, their work to illuminate the mechanisms by which cells store, maintain and use tiny droplets of energy-rich oil is more than additive

A new study led by researchers at Memorial Sloan Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.

… Friday, February 29, 2008 A new study led by researchers at Memorial Sloan Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia. The protein, called AML1, plays a critical role in the

In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care.

… Saturday, December 6, 2014 In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance

Learn what detection of the polio virus in New York State means for you.

… Monday, September 12, 2022 Polio has been in the news after the poliovirus was detected in wastewater samples of several New York counties — including New York City — and a person was identified as having the disease by New York health officials in July. On September 9, Gov. Kathy Hochul declared a state

A new study from Memorial Sloan Kettering Cancer Center has found that high-dose radiation therapy administered alongside systemic therapy in patients with metastatic non-small cell lung cancer can help extend progression free survival.

… Sunday, October 24, 2021 A new study from Memorial Sloan Kettering Cancer Center found that high-dose radiation therapy administered alongside systemic therapy in patients with metastatic non-small cell lung cancer can help extend progression free survival. This is the first and largest randomized clinical

Epcoritamab plus R2 resulted in substantial increases in the objective response rate and progression-free survival compared to R2 alone, the co-primary endpoints of the trial. The triplet combination also outperformed the standard-of-care on the secondary endpoints of complete response rate and duration of response. Lorenzo Falchi, MD, presented the latest results for the study at the American Society of Hematology's 67th Annual Meeting and Exposition in Florida.

… Sunday, December 7, 2025 On November 18, 2025, the U.S. Food and Drug Administration (FDA) approved the triplet epcoritamab plus lenalidomide and rituximab (R 2 ) for patients with relapsed or refractory follicular lymphoma, based on groundbreaking results from the phase 3 EPCORE FL-1 Trial ( NCT05409066

Learn about a possible new treatment approach for soft tissue sarcomas.

… Monday, February 5, 2024 Epithelioid sarcoma , a rare aggressive cancer that usually strikes young adults, and rhabdoid tumors , which affect children, have long been difficult to treat. But the outlook for people with these subtypes of soft tissue sarcoma brightened in 2020 when the Food and Drug Administration

The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non-small cell lung cancer with an alteration called an NRG1 gene fusion, based on a phase 2 clinical trial led by an MSK investigator.

… Thursday, February 6, 2025 Zenocutuzumab (Bizengri ® ) is effective at treating many patients with advanced  pancreatic cancer or  non-small cell lung cancer (NSCLC)  that has an alteration called an  NRG1  gene fusion and whose disease progressed after other treatments, according to a study published